BeiGene, Ltd. (NASDAQ:BGNE) Shares Acquired by Barings LLC

Barings LLC increased its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 66.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,763 shares of the company’s stock after buying an additional 20,663 shares during the quarter. Barings LLC owned about 0.05% of BeiGene worth $7,385,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in BGNE. Headlands Technologies LLC purchased a new stake in shares of BeiGene during the 1st quarter valued at approximately $50,000. Benjamin F. Edwards & Company Inc. raised its holdings in BeiGene by 51.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after buying an additional 279 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in BeiGene during the fourth quarter worth about $183,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of BeiGene in the 4th quarter valued at approximately $215,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at BeiGene

In related news, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Julia Aijun Wang sold 472 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $143.90, for a total transaction of $67,920.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Titus B. Ball sold 137 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,210 shares of company stock worth $2,269,721. 7.43% of the stock is currently owned by insiders.

BeiGene Price Performance

BeiGene stock opened at $211.15 on Thursday. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $215.00. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The stock has a market cap of $20.49 billion, a P/E ratio of -27.89 and a beta of 0.61. The company has a fifty day simple moving average of $173.90 and a 200-day simple moving average of $162.68.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. The business had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business’s quarterly revenue was up 56.1% on a year-over-year basis. During the same quarter last year, the company earned ($3.64) EPS. Equities analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on BGNE shares. Citigroup upped their price target on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their target price on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, Bank of America lowered their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $237.07.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.